Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients

Wang, Bo; Zhou, Meng; Shi, Yue-Yu; Chen, Xing-Lei; Ren, Yue-Xiang; Yang, Yuan-Zhong; Tang, Lu-Ying; Ren, Ze-Fang

doi:10.1007/s00428-023-03534-5

Cited by 2 publications

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ [138][139][140][141][142][143] Moreover, mutations in genes coding for chromatin remodeling proteins, histones, or enzymes that modify histones and DNA are common in various types of cancers like lymphomas that contain activating mutations in EZH2 and leukemias presenting MLLfusion proteins with the methylation of H3K79 driven by the histone methyltransferase DOTL1 [135,136]. These mutations can disrupt the delicate balance of chromatin dynamics, leading to inappropriate gene expression and the silencing of tumor suppressor genes or activation of oncogenes, ultimately contributing to oncogenesis and the proliferation of cancer cells [111].…”

Section: H4k16acmentioning

confidence: 99%

Determinants of Chromatin Organization in Aging and Cancer—Emerging Opportunities for Epigenetic Therapies and AI Technology

Castilho,

Palomares

et al. 2024

Genes

View full text Add to dashboard Cite

This review article critically examines the pivotal role of chromatin organization in gene regulation, cellular differentiation, disease progression and aging. It explores the dynamic between the euchromatin and heterochromatin, coded by a complex array of histone modifications that orchestrate essential cellular processes. We discuss the pathological impacts of chromatin state misregulation, particularly in cancer and accelerated aging conditions such as progeroid syndromes, and highlight the innovative role of epigenetic therapies and artificial intelligence (AI) in comprehending and harnessing the histone code toward personalized medicine. In the context of aging, this review explores the use of AI and advanced machine learning (ML) algorithms to parse vast biological datasets, leading to the development of predictive models for epigenetic modifications and providing a framework for understanding complex regulatory mechanisms, such as those governing cell identity genes. It supports innovative platforms like CEFCIG for high-accuracy predictions and tools like GridGO for tailored ChIP-Seq analysis, which are vital for deciphering the epigenetic landscape. The review also casts a vision on the prospects of AI and ML in oncology, particularly in the personalization of cancer therapy, including early diagnostics and treatment optimization for diseases like head and neck and colorectal cancers by harnessing computational methods, AI advancements and integrated clinical data for a transformative impact on healthcare outcomes.

show abstract

Section: H4k16acmentioning

confidence: 99%

Determinants of Chromatin Organization in Aging and Cancer—Emerging Opportunities for Epigenetic Therapies and AI Technology

Castilho,

Palomares

et al. 2024

Genes

View full text Add to dashboard Cite

show abstract

Cohort profile: Guangzhou breast cancer study (GBCS)

Wang,

Li,

Xiao

et al. 2024

Eur J Epidemiol

View full text Add to dashboard Cite

The Guangzhou Breast Cancer Study (GBCS) is a patient-based prospective cohort study designed to identify risk factors and underlying mechanisms for breast cancer (BC) incidence and prognosis, specifically addressing the need for individualized prevention in South China, where BC incidence is notably high. Based in Guangzhou, China, the GBCS began recruitment in 2008, comprises three complementary studies: the Guangzhou breast cancer cohort with 5471 breast cancer patients, a case–control study with 1551 cases and 1605 controls, and an immunohistochemistry (IHC) cohort with 1063 breast cancer patients. Participants are primarily aged 41–60 years. Cohort follow-up is conducted every three months in the first year, every six months in the second and third years, and annually thereafter. High follow-up rates have been achieved until 2023, with 73.5% for the Guangzhou breast cancer cohort and 98.6% for the IHC cohort still active. Baseline data collection included demographic characteristics and breast cancer risk factors, while follow-up data included survival, treatment details, disease history, occupational history, post-diagnostic lifestyle, and laboratory measures, including genetic markers, proteins, and environmental exposures. The study encourages global collaborations and invites interested researchers to contact the corresponding author at xulin27@ mail.sysu.edu.cn with specific research ideas or proposals.

show abstract

Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients

Cited by 2 publications

References 37 publications

Determinants of Chromatin Organization in Aging and Cancer—Emerging Opportunities for Epigenetic Therapies and AI Technology

Determinants of Chromatin Organization in Aging and Cancer—Emerging Opportunities for Epigenetic Therapies and AI Technology

Cohort profile: Guangzhou breast cancer study (GBCS)

Contact Info

Product

Resources

About